Dataset from A Phase III, Randomized, Multi-Centre, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) Versus SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

The aim of this study was to investigate the safety and efficacy of SPD476 2.4 g/day given
twice daily ([BID] ie 1.2 g/day BID) and SPD476 4.8g/day given QD compared to placebo in
subjects with acute, mild to moderate ulcerative colitis.